SCHEMBL2154229

SCHEMBL2154229

CNC(=O)/C(=N/O)c1ccccc1O

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 7/20 0.47
TSHR P16473 3/20 0.47
KDM4E B2RXH2 9/20 0.46
HPGD P15428 8/20 0.46
ALDH1A1 P00352 6/20 0.46
SMN1; SMN2 Q16637 3/20 0.44
GAA P10253 2/20 0.44
MPO P05164 1/20 0.44
HIF1A Q16665 1/20 0.44
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA2 P00918 1/20 0.44
HMGB1 P09429 1/20 0.44
CA4 P22748 1/20 0.44
CA6 P23280 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
NAPRT Q6XQN6 1/20 0.44
CA14 Q9ULX7 1/20 0.44
HSD17B10 Q99714 6/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2154230 1.00 LMNA (0.47) LMNATSHRKDM4EHPGDALDH1A1
SCHEMBL6626532 1.00 LMNA (0.47) LMNATSHRKDM4EHPGDALDH1A1
SCHEMBL6626327 0.86 LMNA (0.47) LMNATSHRKDM4EHPGDALDH1A1
SCHEMBL6626324 0.86 LMNA (0.47) LMNATSHRKDM4EHPGDALDH1A1
SCHEMBL2154012 0.82 HPGD (0.43) KDM4EHPGDSMN1; SMN2GAANPC1
SCHEMBL2154017 0.82 HPGD (0.43) KDM4EHPGDSMN1; SMN2GAANPC1
SCHEMBL8846182 0.82 HPGD (0.43) KDM4EHPGDSMN1; SMN2GAANPC1
SCHEMBL3370228 0.81 LMNA (0.51) LMNATSHRKDM4EHPGDALDH1A1
SCHEMBL3370230 0.81 LMNA (0.51) LMNATSHRKDM4EHPGDALDH1A1
SCHEMBL5195934 0.81 LMNA (0.51) LMNATSHRKDM4EHPGDALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20130040993-A1 FUNGICIDE HYDROXIMOYL-HETEROCYCLES DERIVATIVES BAYER CROPSCIENCE AG (DE) 2013-02-14 US claimed
EP-2519502-A2 FUNGICIDAL HYDROXIMOYL-HETEROCYCLES DERIVATIVES Bayer CropScience AG (DE) 2012-11-07 EP claimed
WO-2011080254-A2 FUNGICIDE HYDROXIMOYL-HETEROCYCLES DERIVATIVES BAYER CROPSCIENCE AG (DE) 2011-07-07 WO claimed
US-9000012-B2 Fungicide hydroximoyl-heterocycles derivatives BAYER CROPSCIENCE AG (DE) 2015-04-07 US disclosed
US-20130040993-A1 FUNGICIDE HYDROXIMOYL-HETEROCYCLES DERIVATIVES BAYER CROPSCIENCE AG (DE) 2013-02-14 US disclosed
EP-2519502-A2 FUNGICIDAL HYDROXIMOYL-HETEROCYCLES DERIVATIVES Bayer CropScience AG (DE) 2012-11-07 EP disclosed
WO-2011080254-A2 FUNGICIDE HYDROXIMOYL-HETEROCYCLES DERIVATIVES BAYER CROPSCIENCE AG (DE) 2011-07-07 WO disclosed
CN-1537096-A Method for producing (2E)-2-(hydroxyphenyl)-2-(alkoxyimino)-N-methylacetamides �ݶ�ũ�����ѧ�ɷݹ�˾ 2004-10-13 CN disclosed
US-20040186318-A1 Method for producing (2e)-2-(hydroxyphenyl-2-(alkoxyimino)-n-methylacetamides BAYER CROPSCIENCE AG (DE) 2004-09-23 US disclosed
EP-1414789-A1 METHOD FOR PRODUCING (2E)-2-(HYDROXYPHENYL)-2-(ALKOXYIMINO)-N-METHYLACETAMIDES Bayer CropScience AG (DE) 2004-05-06 EP disclosed
WO-2003014065-A1 METHOD FOR PRODUCING (2E)-2-(HYDROXYPHENYL)-2-(ALKOXYIMINO)-N-METHYLACETAMIDES BAYER CROPSCIENCE AG (DE) 2003-02-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040186318-A1 Method for producing (2e)-2-(hydroxyphenyl-2-(alkoxyimino)-n-methylacetamides HMOX2, CYP1A2, PTGS2 LMNA 1227/4885TSHR 4445/4885KDM4E 1620/4885
US-20130040993-A1 FUNGICIDE HYDROXIMOYL-HETEROCYCLES DERIVATIVES HAAO, HPD, CYP51A1 LMNA 2986/4885TSHR 3554/4885KDM4E 278/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.